Physician profile
Sharon Li
NPI 1508894874
$3,116.42
in general payments reported to CMS, 2019-2025
36 companies · $374 in 2025
The $374 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $613 · 2021: $821 · 2022: $181 · 2023: $420 · 2024: $51.84 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $845.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $413.99 | 2019-2023 | Xtandi |
| Antares Pharma, INC. | $321.44 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Boston Scientific Corporation | $284.77 | 2019-2023 | Rezum Generator |
| Bayer Healthcare Pharmaceuticals INC. | $240.82 | 2019-2025 | |
| Coloplast Corp | $202.99 | 2019-2023 | Titan |
| Olympus America INC. | $185.28 | 2021-2025 | Itind System, Uretero-Reno Videoscope |
| Pfizer INC. | $161.45 | 2019-2021 | |
| Hollister Incorporated | $159.18 | 2020-2022 | |
| Janssen Biotech, INC. | $151.70 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $122.10 | 2019-2022 | |
| Koelis INC. | $98.86 | 2021 | |
| Dendreon Pharmaceuticals LLC | $72.59 | 2019-2020 | |
| Clarus Therapeutics INC. | $72.44 | 2021 | |
| Allergan, INC. | $66.40 | 2019-2021 | |
| Tolmar Pharmaceuticals, INC. | $53.13 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 180 Medical, INC. | $48.96 | 2020-2021 | |
| Bioventus LLC | $45.59 | 2022 | |
| Therapeuticsmd, INC. | $42.00 | 2019-2020 | |
| Amgen INC. | $34.08 | 2019-2020 | |
| Tolmar, INC. | $32.29 | 2024-2025 | Jatenzo, Eligard |
| Merck Sharp & Dohme LLC | $29.30 | 2021 | |
| Axonics, INC. | $27.85 | 2021 | |
| Ferring Pharmaceuticals INC. | $26.91 | 2019 | |
| Medtronic USA, INC. | $23.48 | 2020 | |
| Acerus Pharmaceuticals Corporation | $23.01 | 2020 | |
| Abbott Laboratories | $21.96 | 2025 | Freestyle Libre 3 |
| Seapearl East, INC | $19.07 | 2023 | |
| Procept Biorobotics Corporation | $18.39 | 2019 | |
| Rochester Medical Corporation | $17.84 | 2019 | |
| Myovant Sciences INC. | $16.55 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $16.07 | 2025 | Bard Urinary Drainage Bag |
| Urovant Sciences INC | $14.94 | 2021 | |
| Zyla Life Sciences, INC. | $13.98 | 2019 | |
| Duchesnay USA Incorporated | $13.47 | 2019 | |
| Avadel Specialty Pharmaceuticals, LLC | $11.89 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.